The Microenvironment of Human Neuroblastoma Supports the Activation of Tumor-associated T Lymphocytes

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2013 Jun 27

PMID 23802089

Citations 24

Authors

Lena-Maria Carlson

Anna De Geer

Baldur Sveinbjornsson

Abiel Orrego

Tommy Martinsson

Per Kogner

Jelena Levitskaya

Affiliations

Soon will be listed here.

Abstract

Tumor infiltration by lymphocytes has been linked to improved clinical outcome in children with neuroblastoma (NB) but T-cell activation has never been demonstrated to occur within the NB microenvironment. Here we show that tumor-associated lymphocytes (TALs) obtained from lesions representing all genetic subsets of NB and autologous peripheral blood lymphocytes (PBLs) analyzed on the day of tumor excision differed in composition, phenotype and functional characteristics. The NB microenvironment appeared to promote the accumulation of CD3CD8 T cells and contained a larger proportion of T cells expressing the interleukin-2 receptor α chain (CD25) and manifesting an effector memory (CCR7CD45RA) phenotype. Accordingly, the stimulation of PBLs with autologous tumor cells in short-term cultures increased the proportion of effector memory T cells, upregulated CD25, stimulated the expression of the T1 cytokines interferon γ and tumor necrosis factor α, and reduced the expression of transforming growth factor β. In situ proliferation as well as a characteristic pattern of T-cell receptor aggregation at the contact sites with malignant cells was revealed by the immunohistochemical staining of TALs in primary tumors, indicating that the NB milieu is compatible with the activation of the immune system. Our results are compatible with the hypothesis that CD8 T cells are specifically activated within the NB microenvironment, which appears to be permissive for effector memory responses.

Citing Articles

Expansion of tumor-infiltrating and marrow-infiltrating lymphocytes from pediatric malignant solid tumors.

Metts J, Rodriguez-Valentin M, Hensel J, Alfaro A, Snyder C, Binitie O Cytotherapy. 2024; 27(1):29-35.

PMID: 39243253 PMC: 11668621. DOI: 10.1016/j.jcyt.2024.08.002.

Integrative analysis of multi-omics data for discovery of ferroptosis-related gene signature predicting immune activity in neuroblastoma.

Hu J, Song F, Kang W, Xia F, Song Z, Wang Y Front Pharmacol. 2023; 14:1162563.

PMID: 37521469 PMC: 10373597. DOI: 10.3389/fphar.2023.1162563.

Concurrent application of interferon-gamma and vincristine inhibits tumor growth in an orthotopic neuroblastoma mouse model.

Zeki J, Yavuz B, Wood L, Shimada H, Kaplan D, Chiu B Pediatr Surg Int. 2023; 39(1):241.

PMID: 37500800 DOI: 10.1007/s00383-023-05523-w.

Targeted immune activation in pediatric solid tumors: opportunities to complement local control approaches.

Vonderhaar E, Dwinell M, Craig B Front Immunol. 2023; 14:1202169.

PMID: 37426669 PMC: 10325564. DOI: 10.3389/fimmu.2023.1202169.

Impaired Antitumor Immune Response in -amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment.

Kacher J, Manches O, Aspord C, Sartelet H, Chaperot L Cancer Res Commun. 2023; 2(7):577-589.

PMID: 36923280 PMC: 10010397. DOI: 10.1158/2767-9764.CRC-21-0134.

References

De Geer A, Carlson L, Kogner P, Levitskaya J . Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma. Cancer Immunol Immunother. 2007; 57(5):731-43. PMC: 11031004. DOI: 10.1007/s00262-007-0412-2. View

Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang C . Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2010; 103(3):264-72. DOI: 10.1093/jnci/djq524. View

Lee S, Margolin K . Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep. 2012; 14(5):468-74. PMC: 3462483. DOI: 10.1007/s11912-012-0257-5. View

Sakaguchi S, Miyara M, Costantino C, Hafler D . FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010; 10(7):490-500. DOI: 10.1038/nri2785. View

Caren H, Kryh H, Nethander M, Sjoberg R, Trager C, Nilsson S . High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A. 2010; 107(9):4323-8. PMC: 2840092. DOI: 10.1073/pnas.0910684107. View

Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A . Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009; 30(7):1073-81. DOI: 10.1093/carcin/bgp127. View

LAUDER I, Aherne W . The significance of lymphocytic infiltration in neuroblastoma. Br J Cancer. 1972; 26(4):321-30. PMC: 2008644. DOI: 10.1038/bjc.1972.43. View

Song L, Asgharzadeh S, Salo J, Engell K, Wu H, Sposto R . Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest. 2009; 119(6):1524-36. PMC: 2689106. DOI: 10.1172/JCI37869. View

Sadeghi A, Pauler L, Anneren C, Friberg A, Brandhorst D, Korsgren O . Large-scale bioreactor expansion of tumor-infiltrating lymphocytes. J Immunol Methods. 2010; 364(1-2):94-100. DOI: 10.1016/j.jim.2010.11.007. View

10.

Martin R, Beckwith J . Lymphoid infiltrates in neuroblastomas: their occurrence and prognostic significance. J Pediatr Surg. 1968; 3(1):161-4. DOI: 10.1016/0022-3468(68)91005-1. View

11.

Rosenberg S, Yang J, Sherry R, Kammula U, Hughes M, Phan G . Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011; 17(13):4550-7. PMC: 3131487. DOI: 10.1158/1078-0432.CCR-11-0116. View

12.

Mahmoud S, Paish E, Powe D, Macmillan R, Grainge M, Lee A . Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29(15):1949-55. DOI: 10.1200/JCO.2010.30.5037. View

13.

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

14.

Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A . Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011; 71(17):5670-7. DOI: 10.1158/0008-5472.CAN-11-0268. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg R, Abrahamsson J . High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics. 2008; 9:353. PMC: 2527340. DOI: 10.1186/1471-2164-9-353. View

17.

Pule M, Savoldo B, Myers G, Rossig C, Russell H, Dotti G . Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14(11):1264-70. PMC: 2749734. DOI: 10.1038/nm.1882. View

18.

Decock A, Ongenaert M, Vandesompele J, Speleman F . Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings. Epigenetics. 2011; 6(8):962-70. DOI: 10.4161/epi.6.8.16516. View

19.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

20.

Kroesen M, Lindau D, Hoogerbrugge P, Adema G . Immunocombination therapy for high-risk neuroblastoma. Immunotherapy. 2012; 4(2):163-74. DOI: 10.2217/imt.11.169. View